1. FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL. (June 2017) Authors: Kahl, B.; Hamadani, M.; Caimi, P.F.; Reid, E.G.; Havenith, K.; He, S.; Feingold, J.M.; O'Connor, O.A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA. (June 2017) Authors: Horwitz, S.M.; Fanale, M.A.; Spira, A.I.; Havenith, K.; He, S.; Feingold, J.M.; Hamadani, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 270 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗